Haemonetics

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Haemonetics reports robust Q1 earnings, eyes U.S. growth amid challenges

Haemonetics delivered strong financial performance in Q1 fiscal 2023, driven by robust revenue growth in both the Plasma and Hospital segments. The company's focus on the U.S. market and plans for accelerating growth indicate a positive outlook. However, challenges related to potential cuts in donor payments and varying market conditions outside the U.S. require careful navigation.

Haemonetics Corporation reports robust Q1 fiscal 2024 performance and eyes international expansion

Haemonetics Corporation delivered impressive Q1 fiscal 2024 results, driven by strong revenue growth and improved operating income. The company faces challenges in managing inventory replenishment and potential competition in the autoimmune space. However, opportunities lie in leveraging its robust product portfolio and expanding into international markets.

Haemonetics reports strong Q3 performance, eyes European expansion for growth

Haemonetics delivered robust financial results in Q3, driven by strong revenue growth and strategic initiatives. While facing challenges related to staffing and donor issues, the company is well-positioned to leverage opportunities in expanding markets and technological advancements to drive future growth.

Haemonetics posts robust earnings, eyes global expansion for growth

Haemonetics delivered strong financial results in Q4 2023 and fiscal '23, driven by robust revenue growth and improved earnings per share.
The company's focus on key segments like Plasma, Hospital, Hemostasis, and Vascular Closure positions it well for future growth and market expansion.
While facing challenges such as cost pressures and competitive landscapes, Haemonetics remains optimistic about its ability to drive profitability and market share.
Strategic initiatives, including a modest ramp in market resources and international expansion, present opportunities for Haemonetics to capitalize on market demand and enhance shareholder value.

Haemonetics excels in Q1 '24, eyes growth amid challenges

Haemonetics delivered robust financial performance in Q1 '24, with significant revenue growth and margin expansion.
While facing challenges like product recalls, the company remains focused on value creation and growth acceleration strategies.
Opportunities for growth exist through market scaling, product innovations, and leveraging trial implications for demand growth.

Haemonetics posts robust Q2 earnings, eyes U.S. and international growth

Haemonetics reported strong Q2 results with increased earnings and revenue growth. The company's strategic acquisitions and focus on innovation position it well for future expansion. Challenges in the Blood Center segment require attention, but overall, Haemonetics is poised for continued growth.

Haemonetics posts robust Q3 earnings, eyes growth through innovation

Haemonetics delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency improvements.
The company's focus on innovation, technology enhancements, and strategic acquisitions positions it well for future growth and market leadership.
While facing challenges in certain revenue segments, Haemonetics remains poised to capitalize on opportunities for expansion and margin improvement.

Haemonetics posts robust Q4 results, eyes growth through acquisitions

Haemonetics' Q4 2024 performance reflects strong revenue growth and profitability, driven by successful product launches and acquisitions.
While the company faces challenges in margin targets and integration post-acquisitions, strategic focus on innovation and market expansion presents growth opportunities.
Emphasis on non-GAAP measures and regulatory clearances underscores Haemonetics' commitment to transparency and product quality.
Fiscal year 2025 guidance signals a positive outlook for revenue growth and operational efficiency, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Haemonetics (HAE) Up 3.2% Since Last Earnings Report: Can It Continue?

Axonics ModulationTechnologies Inc

Sensus Healthcare

Axonics is breaking out from a three-weeks-tight pattern after announcing it has begin treating patients in Canada. The post Medical Device Maker Announces New Patients, Shoots Past Buy Point appeared first on Investor's Business Daily.

Medical Device Maker Announces New Patients, Shoots Past Buy Point

We reiterate the buy thesis on Haemonetics Corp. Strong Q2 earnings alongside healthy plasma collection market fundamentals are appealing factors.

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.

Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail

Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.

Here's Why You Should Retain Haemonetics (HAE) Stock Now

According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.

Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business

BOSTON , Aug. 29, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced an agreement with Epic, a leading Electronic Health Record (EHR) system, to offer Haemonetics' SafeTrace Tx® blood bank information system to Epic's global network of hospitals. SafeTrace Tx is a specialized transfusion management system used in the blood bank to provide comprehensive management of patients and blood products and to assist in determining blood product suitability for patient transfusion.

Haemonetics Announces Agreement to Offer Enhanced Transfusion Management Software to Epic's Global Network of Hospitals

BOSTON , Aug. 23, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 8:45 a.m. ET. The public may access Mr.

Haemonetics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Investors are optimistic about Haemonetics' (HAE) potential in its Plasma franchise.

Haemonetics (HAE) Hits 52-Week High: What's Aiding the Stock?

Bio-Rad Laboratories

Lantheus Holdings

Zimmer Biomet Hlds

Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.

4 Stocks to Watch Amid Recovering Medical Products Industry

Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock

Does Haemonetics (HAE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Haemonetics (HAE) is a Great Momentum Stock to Buy

Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up

Haemonetics Corporation (NYSE:HAE ) Q1 2023 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Olga Guyette - Director, IR and Treasury Chris Simon - CEO James D'Arecca - CFO Conference Call Participants Larry Solow - CJS Securities Drew Ranieri - Morgan Stanley Andrew Cooper - Raymond James Mike Matson - Needham & Company Michael Petusky - Barrington Research David Turkaly - JMP Securities Anthony Petrone - Mizuho Securities Operator Good day, and welcome to Haemonetics Corporation's First Quarter Fiscal 2023 Earnings Call. [Operator Instructions] As a reminder, this call is being recorded.

Haemonetics Corporation (HAE) CEO Chris Simon on Q1 2023 Results - Earnings Call Transcript

Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates

Haemonetics easily beat fiscal first-quarter estimates on Wednesday and raised its outlook for the year. HAE stock popped.

Haemonetics Surges Closer To A Breakout After Squashing Quarterly Estimates, Raising Guidance

Financial release accessible online BOSTON , Aug. 10, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal 2023, which ended July 2, 2022, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.

Haemonetics 1st Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website

Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).

Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises

Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.

Here's Why You Should Retain Haemonetics (HAE) Stock For Now

BOSTON , July 7, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2023 financial results at 6:00 am EDT on Wednesday, August 10, 2022. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on August 10, 2022.

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2023 Results: August 10, 2022

BOSTON , June 24, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has fully commenced operations at its new manufacturing Center of Excellence in Clinton, PA. The custom-built facility occupies approximately 200,000 square feet at 1300 Clifford Ball Drive in Clinton Commerce Park near Pittsburgh International Airport.

Haemonetics Completes Move to New Manufacturing Facility in Clinton, PA

The debate on Haemonetics largely rests on growth in the blood plasma market. More than 35% of revenues are exposed to this segment, and growth of the market has been volatile in recent years.

Haemonetics: Upside Case Hinges On Blood Plasma Collection Market

Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?

BOSTON , June 6, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) has posted its full lineup of speakers planned for the Company's Investor Day, to be hosted in Boston on Wednesday, June 29, 2022, with presentations beginning at 10:00 AM EDT. Information about scheduled speakers and the agenda for the event can be found at the Company's Investor Relations website at https://irday.haemonetics.com.

Haemonetics Corporation Announces Additional Information Regarding Its Investor Day on June 29, 2022

A strong procedure recovery in the hospital business, the resilience of blood donors in blood centers, and rollouts of Persona technology and NexSys aid Haemonetics (HAE).

News for Haemonetics Stock (HAE)